Anti-cancer nuclear hormone receptor-targeting compounds

A compound of Formula I, or a tautomer, stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof:

• wherein:
• A1 is CH or N;
• A2 is CH or N;
• A3 is N or CR3;
• A4 is C and is a double bond, or A4 is CH and is a single bond, or A4 is N and is a single bond;
• L is
• wherein:
• s is 1, 2, or 3,
• s′ is 0 or 1,
• G1, G2, G3, and G4 are each independently CH or N, and
• L′ and L″ are each independently selected from a bond, CH2, CH2CH2, NHC(O), or C=O;
• R1 is a nuclear receptor-targeting epitope;
• R2 is hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C3-6 cycloalkyl;
• R3 is hydrogen or halo;
• or
• R2 and R3 together with the atoms to which they are attached form a 6-membered heterocyclyl or 6-membered heteroaryl;
• R4 is hydrogen, aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted with one to five R5;
• each R5 is independently halo, cyano, nitro, —OR10, —OC(O)R10, —C(O)OR10, —SR10, —NR10R11, —NR10C(O)R11, —C(O)NR10R11, C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, or C2-12 alkynyl;
• wherein each C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, or C2-12 alkynyl is independently optionally substituted with one to five halo, hydroxyl, or amino;
• R6 is hydrogen, halo, or C1-6 alkyl;
• and
• each R10 and R11 is independently hydrogen or C1-12 alkyl optionally substituted with oxo, halo, hydroxyl, or amino as valency permits;
• or R10 and R11 are taken together with the atoms to which they are attached to form a heterocyclyl optionally substituted by halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl, or amino;
• wherein any hydrogen atom of the moiety in the brackets is replaced with -L-R1.